eShunt 

Initially we will treat patients with some tear production. With the accumulation of experience, we will collect the necessary evidence to encourage surgeons to tackle the most challenging and arid ophthalmic patients, suffering from alkali chemical burn, Stevens-Johnson Syndrome or ocular cicatricial pemphigus.

See previous answer.

Yes, we believe that herpes keratitis patients stand to gain a valid therapeutic modality, which is currently missing in the battery of clinical ophthalmic solutions.

Scarred, opaque and/or vascularized corneas are excellent candidates for the CorNeat KPro.

Yes, laser correction does not interfere with the CorNeat KPro implantation procedure.

Yes, patients with failed corneal grafts are our ideal candidates for implantation.

The major differences between the two implants are i) The Boston KPro utilizes donor cornea tissue to attach the synthetic lens to the eye whereas the CorNeat KPro is completely synthetic eliminating the need for harvesting tissue to bridge the gap between the artificial lens and the patients eye. ii) The Boston KPro provides a narrow field of view both for the patient and the physician. This limits the ability of the practitioner to follow up on the eye’s health and intervene in time. Following implantation of the Boston KPro, access to the internal ocular compartments is blocked thus surgical procedures cannot be carried out. The CorNeat KPro is engineered with bays on the optic’s rim to enable anterior chamber access following implantation and will stay accessible throughout the patient’s life. Posterior chamber access is readily available through the device’s integrating element, which should stay accessible throughout life as well. This will also allow the ophthalmologist to perform regular and thorough follow-up and timely interventions as needed. The CorNeat KPro has a wide field of view similar to the native cornea providing the patient with real-life optics and restoring an aesthetic appearance. iii) The Boston KPro is a temporary solution, which needs to be replaced once every few years, when all goes well, or it permanently damages the eye's visual potential through a variety of complications. The CorNeat KPro is engineered to be a permanent solution with robust integration into the eye’s tissues.

The CorNeat KPro clinical trial is taking place in Israel, Canada, France, the Netherlands and India and are planned to start in the USA in 2026.

The CorNeat KPro launch is planned for 2027.

Initially, the CorNeat KPro will be approved as a second-line treatment, only patients who lack a therapeutic alternative or have failed a corneal transplantation will be eligible for the procedure. Approval of the CorNeat KPro as a first-line treatment is a priority for CorNeat Vision and will follow the initial approval.

Keratoconus patients are suitable candidates for corneal transplantation with positive long-term results. Therefore, they are not ideal candidates for primary implantation. The CorNeat KPro is a viable solution in cases where a Keratoconus patient fails corneal transplantation for any reason, as a second-line treatment.

Such a patient would not be a good candidate as the CorNeat KPro mandates visual potential. Retinal issues, optic nerve function and other issues affecting visual potential need to be dealt with prior to attempting implantation of the CorNeat KPro.

Glaucoma is not a contraindication for the CorNeat KPro implantation. Glaucoma should be a consideration when planning the surgery as adjunct procedures, changes in drug regimen and visual potential might vary between glaucoma patients undergoing CorNeat KPro implantation. These factors impact eligibility and surgical and post-op planning.